Evidence map›Paper›PMID 40940804›Full record

ReviewCells2025

Integrating Macrophages into Human-Engineered Cardiac Tissue.

Yi Peng Zhao, Barry M Fine

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yi Peng ZhaoDepartment of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0009-0005-2905-5675
Barry M FineDepartment of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0001-6298-2888

Funding

STK25 phosphorylates PRKAR1A to regulate PKA signalingR01HL166387 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Barry M. Fine · 2023 to 2026
$2.3M
NHLBI NIH HHS R01 HL166387NIH HHS 5R01HL166387-02
6 · The paper itself

Abstract

Heart disease remains a leading cause of morbidity and mortality worldwide, necessitating the development of in vivo models for therapeutic development. Advances in biomedical engineering in the past decade have led to the promising rise of human-based engineered cardiac tissues (hECTs) using novel scaffolds and pluripotent stem cell derivatives. This has led to a new frontier of human-based models for improved preclinical development. At the same time, there has been significant progress in elucidating the importance of the immune system and, in particular, macrophages, particularly during myocardial injury. This review summarizes new methods and findings for deriving macrophages from human pluripotent stem cells (hPSCs) and advances in integrating these cells into cardiac tissue. Key challenges include immune cell infiltration in 3D constructs, maintenance of tissue architecture, and modeling aged or diseased cardiac microenvironments. By integrating immune components, hECTs can serve as powerful tools to unravel the complexities of cardiac pathology and develop targeted therapeutic strategies.

Indexed as

MacrophagesMyocardiumTissue EngineeringAnimalsHumansPluripotent Stem CellsTissue Scaffoldscardiacengineered heart tissueimmune celliPSmacrophage

Identifiers

PMID40940804
PMCPMC12427660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.